These are still heady days for the newly in-power Labour party, not yet passed the 100-day honeymoon period and not yet the target of too much criticism, which, history tells us, will not be too far away.
First Stage Of UK NHS Review 2024: Darzi Delivers His Early Verdict
Government-Ordered Review Has Little For Medtechs To Get Their Teeth Into
Can the new UK government's raw enthusiasm for NHS reform be a catalyst for real change where countless past attempts to address the national provider's shortcomings have failed to hit the spot? And what might the 10-year plan mean for medtech?
More from United Kingdom
• By
Medtech has not yet been spared from the Trump administration’s trade tariffs, which, for UK exporters will be 10% – half the rate applied to EU27 exporters.
• By
Cambridge, UK-based breath biopsy company Owlstone Medical will apply its volatile organic compound analysis platform in an attempt to develop a test for the identification and monitoring of pseudomonas aeruginosa in patients with cystic fibrosis.
• By
Medtech Insight sat down with Anja Streicher, chief marketing officer at Women of Wearables, a global community offering events and education resources to support the femtech industry, to discuss trends in the women's wearables tech market, challenges and innovators pushing the boundaries.
• By
Britain’s medtech system progress, smarter ways of working at the agency and getting smarter AI and digital technologies into circulation for patients, were themes woven through the UK MHRA board’s 18 March meeting.
More from Europe
• By
Cybersecurity, sustainability and regulatory intelligence all need factoring into risk management today as AI and data availability change the goalposts. Eight experts tell Medtech Insight how compliance efforts must adapt.
• By
The IVD industry’s new 10-point plan for healthcare change shows that medtechs will keep calling the German government to account. Tariffs, sector resilience, digital functionality are among the pressing issues industry wants answers to.
• By
Pediatric devices and IVDs are to be a priority. And the European Health Data Space regulation is seen as critical in supporting digital technologies and AI in transforming care.